Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive ...

Guttate psoriasis is a type of psoriasis that shows up on your skin as red, scaly, small, teardrop-shaped spots. Scalp psoriasis is a common skin disorder. It can be a single patch or several ...

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates ...

Medically reviewed by Lindsay Cook, PharmD Fact checked by Khara Scheppmann Psoriasis is usually treated with a combination ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...

The American Academy of Dermatology suggests biologics if you have moderate to severe psoriasis that hasn’t improved using more traditional systemic treatments or can’t tolerate those ...

Results from the separate SCALP study, involving 102 patients with moderate-to-severe scalp psoriasis, showed a significantly higher proportion of patients receiving Cosentyx had 90% plaque ...

Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

Johnson & Johnson (J&J) and Protagonist Therapeutics have announced positive top-line results from a late-stage study of ...

Following the treatment, clients can experience immediate relief. The scalp cleanse is best for those experiencing psoriasis, eczema, dermatitis, dandruff, or a clogged scalp. For more ...